Jhanelle E. Gray, MD, is a Medical Oncologist and the Director of Thoracic Clinical Research in the Department of Thoracic Oncology at H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida. She received her undergraduate degree from the University of Florida and her medical degree from Cornell University Medical College in New York City. Following her internship and residency in Internal Medicine at Cornell, Dr. Gray returned to Florida and completed her Medical Oncology Fellowship at Moffitt. She is a faculty member in the Department of Thoracic Oncology at Moffitt Cancer Center where she has been practicing since 2007.
Although Dr. Gray focuses her clinical attentions on lung cancer, she is also deeply involved in clinical research. She is the lead investigator on many thoracic clinical trials especially research investigating novel drug combinations and personalized treatment to advance the fight against lung cancer. As the Director of Thoracic Clinical Research in the Department of Thoracic Oncology, Dr. Gray directly supervises and manages 26 team members, (including 13 clinical research coordinators, 7 research data specialists, 2 regulatory specialists, a clinical research supervisor , clinical trials office manager, a program coordinator and 2 clinical research coordinator ). Dr. Gray leads the restructuring and development of our clinical trial portfolio and assignment (which currently includes 30 clinical trials with active patients and 15 planned clinical trials currently undergoing regulatory and contracts review). In this role, she fosters the clinical trial development through intra- and extramural collaborations between our medical, surgical, and radiation oncologists, research scientists, pathologists, and epidemiologists in the Department of Thoracic Oncology.
In addition to treating patients and serving as the lead investigator on many thoracic clinical trials, Dr. Gray is an active member of a number of committees at Moffitt, ranging from evaluation of minority accruals in clinical trials to integration of translational research in Phase I through Phase IlI clinical trials.